Matthew Caufield
Stock Analyst at HC Wainwright & Co.
(4.44)
# 323
Out of 5,240 analysts
136
Total ratings
50.4%
Success rate
22.05%
Average return
Main Sectors:
Stocks Rated by Matthew Caufield
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| LENZ LENZ Therapeutics | Maintains: Buy | $48 → $38 | $8.05 | +372.05% | 9 | May 12, 2026 | |
| SRZN Surrozen | Maintains: Buy | $36 → $44 | $30.14 | +45.99% | 5 | May 7, 2026 | |
| TARS Tarsus Pharmaceuticals | Reiterates: Buy | $88 | $64.66 | +36.10% | 3 | May 4, 2026 | |
| IMUX Immunic | Maintains: Buy | $22 → $5 | $12.95 | -61.39% | 9 | Apr 30, 2026 | |
| FBLG FibroBiologics | Maintains: Buy | $4 → $8 | $1.13 | +607.96% | 10 | Apr 16, 2026 | |
| KOD Kodiak Sciences | Reiterates: Buy | $38 → $58 | $39.61 | +46.43% | 10 | Mar 27, 2026 | |
| FDMT 4D Molecular Therapeutics | Reiterates: Buy | $36 | $10.45 | +244.50% | 19 | Mar 20, 2026 | |
| ALDX Aldeyra Therapeutics | Downgrades: Neutral | $10 → $2 | $1.70 | +17.65% | 14 | Mar 18, 2026 | |
| ZBIO Zenas BioPharma | Reiterates: Buy | $44 | $19.93 | +120.77% | 7 | Mar 17, 2026 | |
| ARDX Ardelyx | Maintains: Buy | $10 → $18 | $6.38 | +182.13% | 2 | Feb 20, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $6 | $1.18 | +408.47% | 4 | Feb 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $52 → $56 | $26.86 | +108.49% | 13 | Nov 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $20 → $26 | $12.56 | +107.01% | 11 | Oct 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $12 | $6.26 | +91.69% | 7 | Aug 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $8 | $5.03 | +59.05% | 4 | Jun 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $9 | $9.60 | -6.25% | 8 | May 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $28 | $696.07 | -95.98% | 1 | Aug 22, 2023 |
LENZ Therapeutics
May 12, 2026
Maintains: Buy
Price Target: $48 → $38
Current: $8.05
Upside: +372.05%
Surrozen
May 7, 2026
Maintains: Buy
Price Target: $36 → $44
Current: $30.14
Upside: +45.99%
Tarsus Pharmaceuticals
May 4, 2026
Reiterates: Buy
Price Target: $88
Current: $64.66
Upside: +36.10%
Immunic
Apr 30, 2026
Maintains: Buy
Price Target: $22 → $5
Current: $12.95
Upside: -61.39%
FibroBiologics
Apr 16, 2026
Maintains: Buy
Price Target: $4 → $8
Current: $1.13
Upside: +607.96%
Kodiak Sciences
Mar 27, 2026
Reiterates: Buy
Price Target: $38 → $58
Current: $39.61
Upside: +46.43%
4D Molecular Therapeutics
Mar 20, 2026
Reiterates: Buy
Price Target: $36
Current: $10.45
Upside: +244.50%
Aldeyra Therapeutics
Mar 18, 2026
Downgrades: Neutral
Price Target: $10 → $2
Current: $1.70
Upside: +17.65%
Zenas BioPharma
Mar 17, 2026
Reiterates: Buy
Price Target: $44
Current: $19.93
Upside: +120.77%
Ardelyx
Feb 20, 2026
Maintains: Buy
Price Target: $10 → $18
Current: $6.38
Upside: +182.13%
Feb 6, 2026
Reiterates: Buy
Price Target: $6
Current: $1.18
Upside: +408.47%
Nov 12, 2025
Maintains: Buy
Price Target: $52 → $56
Current: $26.86
Upside: +108.49%
Oct 31, 2025
Maintains: Buy
Price Target: $20 → $26
Current: $12.56
Upside: +107.01%
Aug 15, 2025
Reiterates: Buy
Price Target: $12
Current: $6.26
Upside: +91.69%
Jun 27, 2025
Reiterates: Buy
Price Target: $8
Current: $5.03
Upside: +59.05%
May 19, 2025
Reiterates: Neutral
Price Target: $9
Current: $9.60
Upside: -6.25%
Aug 22, 2023
Reiterates: Buy
Price Target: $28
Current: $696.07
Upside: -95.98%